Volume 5, Issue 2 (12-2023)
pbp 2023, 5(2): 39-47 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Aghdashi M A, Hajahmadi pourrafsanjan M, Mokari T. Evaluation of QTc and Tp-e changes in rheumatoid arthritis and ankylosing spondylitis patients treated with biological drugs. pbp 2023; 5 (2) :39-47
URL: http://pbp.medilam.ac.ir/article-1-206-en.html
URL: http://pbp.medilam.ac.ir/article-1-206-en.html
1- Department of Internal Medicine, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran
2- Department of Cardilogy, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran , hajahmadimojgan@gmail.com
2- Department of Cardilogy, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran , hajahmadimojgan@gmail.com
Abstract: (263 Views)
Background: Tumor necrosis factor-α (TNF-α) antagonists bring about significant improvement in chronic inflammatory diseases such as rheumatoid arthritis (RA) and spondyloarthritis (SpA), but they may have negative myocardial effects. This study aimed to evaluate the changes in QTc and Tp-e in RA and AS patients treated with biological drugs.
Methods: This cross-sectional study included all eligible patients referred to Imam Khomeini Hospital, Urmia, Iran from March 2021 to February 2022 and were randomly divided into two groups (anti-TNF group treated with methotrexate, rituximab, etanercept, adalimumab, infliximab and control group treated with methotrexate). Electrocardiographs (ECG) were performed on all participants at baseline and 6 months after initiation of treatment, and the QT, QTd, and TpTe were calculated with standard procedures.
Result: Of 128 patients with RA or AS, 64 patients were included in the anti-TNF group and control group, separately. There was predominance of male gender: 69 (53.9%) vs. 59 (46.1%) among all patients with mean age of 47.77 years. After 6 months, the anti-TNF group already displayed a shorter mean QT and QTC than control group (418.7±15.6. ms vs. 414.0±17.5 ms, p =0.03; 461.7±25. 0 vs. 448.3±11.2, p=0.2), longer mean TpTE than control group (71.4±6.7 vs. 70.4±7.4, p=0.6). Post treatment increases in the QT were detected exclusively in the subgroup of patients being treated with Infliximab, Etanercept, Adalimumab, Rituximab for RA, which all were significant (P= 0.002, 0.001, 0.001, 0.001, respectively). In contrast, post treatment changes in the QTd and QTdc indices were not outstanding and statistically significant.
Conclusion: This study demonstrated that Tp-e interval and Tp-e/QT ratio were elevated in RA and AS patients. As previously reported, anti-TNF drugs induce a substantial rise in QT and QTc levels, which can pose considerable risks to patients due to their asymptomatic presentation.
Methods: This cross-sectional study included all eligible patients referred to Imam Khomeini Hospital, Urmia, Iran from March 2021 to February 2022 and were randomly divided into two groups (anti-TNF group treated with methotrexate, rituximab, etanercept, adalimumab, infliximab and control group treated with methotrexate). Electrocardiographs (ECG) were performed on all participants at baseline and 6 months after initiation of treatment, and the QT, QTd, and TpTe were calculated with standard procedures.
Result: Of 128 patients with RA or AS, 64 patients were included in the anti-TNF group and control group, separately. There was predominance of male gender: 69 (53.9%) vs. 59 (46.1%) among all patients with mean age of 47.77 years. After 6 months, the anti-TNF group already displayed a shorter mean QT and QTC than control group (418.7±15.6. ms vs. 414.0±17.5 ms, p =0.03; 461.7±25. 0 vs. 448.3±11.2, p=0.2), longer mean TpTE than control group (71.4±6.7 vs. 70.4±7.4, p=0.6). Post treatment increases in the QT were detected exclusively in the subgroup of patients being treated with Infliximab, Etanercept, Adalimumab, Rituximab for RA, which all were significant (P= 0.002, 0.001, 0.001, 0.001, respectively). In contrast, post treatment changes in the QTd and QTdc indices were not outstanding and statistically significant.
Conclusion: This study demonstrated that Tp-e interval and Tp-e/QT ratio were elevated in RA and AS patients. As previously reported, anti-TNF drugs induce a substantial rise in QT and QTc levels, which can pose considerable risks to patients due to their asymptomatic presentation.
Type of Study: Research |
Subject:
Herbal Drugs
Received: 2023/12/18 | Accepted: 2023/12/20 | Published: 2023/12/20
Received: 2023/12/18 | Accepted: 2023/12/20 | Published: 2023/12/20
References
1. Jang DI, Lee AH, Shin HY, Song HR, Park JH, Kang TB, Lee SR, Yang SH. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics. International journal of molecular sciences. 2021 Mar 8;22(5):2719.
2. van Loo G, Bertrand MJ. Death by TNF: a road to inflammation. Nature Reviews Immunology. 2023 May;23(5):289-303. doi.org/10.1038/s41577-022-00792-3
3. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.N Engl J Med. 1990; 323:236–241. doi: 10.1056/NEJM199007263230405.
4. Andretto V, Dusi S, Zilio S, Repellin M, Kryza D, Ugel S, Lollo G. Tackling TNF-α in autoinflammatory disorders and autoimmune diseases: from conventional to cutting edge in biologics and RNA-based nanomedicines. Advanced Drug Delivery Reviews. 2023 Sep 1:115080. doi.org/10.1016/j.addr.2023.115080
5. Cantini F, Niccoli L, Nannini C, Cassara E, Kaloudi O, Favalli EG, Becciolini A, Biggioggero M, Benucci M, Gobbi FL, Grossi V. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. InSeminars in Arthritis and Rheumatism 2016 Apr 1 (Vol. 45, No. 5, pp. 519-532). WB Saunders. doi.org/10.1016/j.semarthrit.2015.10.001
6. Hunter TM, Boytsov NN, Zhang X, Schroeder K, Michaud K, Araujo AB. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004–2014. Rheumatology international. 2017 Sep;37:1551-7. doi: 10.1007/s00296-017-3726-1. Epub 2017 Apr 28.
7. Lee TH, Song GG, Choi SJ, Seok H, Jung JH. Relationship of rheumatoid arthritis and coronary artery disease in the Korean population: a nationwide cross-sectional study. Advances in Rheumatology. 2019 Sep 9;59. DOI: 10.1186/s42358-019-0084-6
8. Park E, Griffin J, Bathon JM. Myocardial dysfunction and heart failure in rheumatoid arthritis. Arthritis & Rheumatology. 2022 Feb;74(2):184-99. DOI: 10.1002/art.41979
9. Wenker KJ, Quint JM. Ankylosing Spondylitis. [Updated 2023 Jun 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470173/
10. Aksoy H, Okutucu SE, Sayin BY, Ercan EA, Kaya EB, Ozdemir O, Inanici F, Aytemir K, Oto A. Assessment of cardiac arrhythmias in patients with ankylosing spondylitis by signal-averaged P wave duration and P wave dispersion. European Review for Medical & Pharmacological Sciences. 2016 Mar 15;20(6).
11. Adlan AM. Inflammation and Heart Rate–corrected QT Interval: Evidence for a Potentially Reversible Cause of Sudden Death in Patients with Rheumatoid Arthritis?. The Journal of Rheumatology. 2018 Dec 1;45(12):1609-10. DOI: https://doi.org/10.3899/jrheum.180921
12. Lazzerini PE, Abbate A, Boutjdir M, Capecchi PL. Fir (e) ing the rhythm: inflammatory cytokines and cardiac arrhythmias. JACC: Basic to Translational Science. 2023 Feb 15. doi.org/10.1016/j.jacbts.2022.12.004
13. Xie L, Li Z, Zhou Y, He Y, Zhu J. Computational Diagnostic Techniques for Electrocardiogram Signal Analysis. Sensors (Basel). 2020 Nov 5;20(21):6318. doi: 10.3390/s20216318.
14. Monitillo F, Leone M, Rizzo C, Passantino A, Iacoviello M. Ventricular repolarization measures for arrhythmic risk stratification. World J Cardiol. 2016 Jan 26;8(1):57-73. doi: 10.4330/wjc.v8.i1.57.
15. Akboğa MK, Gülcihan Balcı K, Yılmaz S, Aydın S, Yayla Ç, Ertem AG, Ünal S, Balcı MM, Balbay Y, Aras D, Topaloğlu S. Tp-e interval and Tp-e/QTc ratio as novel surrogate markers for prediction of ventricular arrhythmic events in hypertrophic cardiomyopathy. Anatol J Cardiol. 2017 Jul;18(1):48-53. doi: 10.14744/AnatolJCardiol.2017.7581.
16. Kahraman S, Dogan A, Demirci G, Guler A, Kalkan AK, Uzun F, Kurtoglu N, Erturk M, Kalkan ME. The association between Tp-e interval, Tp-e/QT, and Tp-e/QTc ratios and coronary artery disease spectrum and syntax score. International Journal of Cardiovascular Sciences. 2021 Jan 22;34:179-87.
17. Zhao X , Xie Z , Chu Y , Yang L , Xu W , Yang X, et al . Association between Tp-e/QT ratio and prognosis in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction . Clin Cardiol . 2012 ; 35 : 559 – 64 . DOI: 10.1002/clc.22022
18. Zehir R, Karabay CY, Kalaycı A, Akgün T, Kılıçgedik A, Kırma C. Evaluation of Tpe interval and Tpe/QT ratio in patients with slow coronary flow. Anatol J Cardiol. 2015 Jun;15(6):463-7. doi: 10.5152/akd.2014.5503
19. Yenerçağ M, Arslan U, Doğduş M, Günal Ö, Öztürk ÇE, Aksan G, Erdoğan G, Gül S, Yontar OC, Şen A. Evaluation of electrocardiographic ventricular repolarization variables in patients with newly diagnosed COVID-19. Journal of Electrocardiology. 2020 Sep 1;62:5-9.
20. Day CP, McComb JM, Campbell RW. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br Heart J. 1990 Jun;63(6):342-4. doi: 10.1136/hrt.63.6.342.
21. Di Franco M, Paradiso M, Ceccarelli F, Scrivo R, Spinelli FR, Iannuccelli C, et al. Biological drug treatment of rheumatoid arthritis and spondyloarthritis: effects on QT interval and QT dispersion. The Journal of rheumatology. 2012;39(1):41-5.
22. Amaya-Amaya J, Montoya-Sánchez L, Rojas-Villarraga A. Cardiovascular involvement in autoimmune diseases. BioMed research international. 2014 Jan 1;2014. https://doi.org/10.1155/2014/367359
23. Noori NM, Shahramian I, Teimouri A, Keyvani B, Mahjoubifard M. Serum Levels of Tumor Necrosis Factor-α and Interleukins in Children with Congenital Heart Disease. J Tehran Heart Cent. 2017 Jan;12(1):15-22. PMID: 28469687; PMCID: PMC5409944.
24. Sarzi-Puttini P, Atzeni F, Doria A, Iaccarino L, Turiel M. Tumor necrosis factor-alpha, biologic agents and cardiovascular risk. Lupus 2005;14:780-4.
25. Rawla P. Cardiac and vascular complications in rheumatoid arthritis. Reumatologia. 2019;57(1):27-36. doi: 10.5114/reum.2019.83236.
26. Legge A, Hanly JG. Managing premature atherosclerosis in patients with chronic inflammatory diseases. CMAJ. 2018 Apr 9;190(14):E430-E439. doi: 10.1503/cmaj.170776.
27. Chauhan K, Ackerman MJ, Crowson CS, Matteson EL, Gabriel SE. Population-based study of QT interval prolongation in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2015 Jan-Feb;33(1):84-9.
28. Acar G, Yorgun H, İnci MF, Akkoyun M, Bakan B, Nacar AB, Dirnak I, Cetin GY, Bozoglan O. Evaluation of Tp-e interval and Tp-e/QT ratio in patients with ankylosing spondylitis. Modern Rheumatology. 2013 Apr 12:1-6.
29. Masoud S, Lim PB, Kitas GD, Panoulas V. Sudden cardiac death in patients with rheumatoid arthritis. World J Cardiol. 2017 Jul 26;9(7):562-573. doi: 10.4330/wjc.v9.i7.562.
30. Hayward RM, Tseng ZH. Arrhythmias in Complex Congenital Heart Disease. Card Electrophysiol Clin. 2014 Sep 1;6(3):623-634. doi: 10.1016/j.ccep.2014.05.014.
31. Janse van Rensburg DC, Ker JA, Grant CC, Fletcher L. Autonomic impairment in rheumatoid arthritis. International journal of rheumatic diseases. 2012 Aug;15(4):419-26.
32. Gürdal A, Eroğlu H, Helvaci F, Sümerkan MÇ, Kasali K, Çetin Ş, Aksan G, Kiliçkesmez K. Evaluation of Tp-e interval, Tp-e/QT ratio and Tp-e/QTc ratio in patients with subclinical hypothyroidism. Ther Adv Endocrinol Metab. 2017 Mar;8(3):25-32. doi: 10.1177/2042018816684423.
33. Ajibare AO, Olabode OP, Fagbemiro EY, Akinlade OM, Akintunde AA, Akinpelu OO, Olatunji LA, Soladoye AO, Opadijo OG. Assessment of Ventricular Repolarization in Sickle Cell Anemia Patients: The Role of QTc Interval, Tp-e Interval and Tp-e/QTc Ratio and Its Gender Implication. Vasc Health Risk Manag. 2020 Dec 7;16:525-533. doi: 10.2147/VHRM.S259766.
34. Panikkath R, Reinier K, Uy-Evanado A, Teodorescu C, Hattenhauer J, Mariani R, Gunson K, Jui J, Chugh SS. Prolonged Tpeak-to-tend interval on the resting ECG is associated with increased risk of sudden cardiac death. Circulation: Arrhythmia and Electrophysiology. 2011 Aug;4(4):441-7.
35. Saour BM, Wang JH, Lavelle MP, Mathew RO, Sidhu MS, Boden WE, Sacco JD, Costanzo EJ, Hossain MA, Vachharanji T, Alrefaee A, Asif A. TpTe and TpTe/QT: novel markers to predict sudden cardiac death in ESRD? J Bras Nefrol. 2019 Jan-Mar;41(1):38-47. doi: 10.1590/2175-8239-JBN-2017-0021.
36. Niemeijer MN, van den Berg ME, Eijgelsheim M, van Herpen G, Stricker BH, Kors JA, Rijnbeek PR. Short-term QT variability markers for the prediction of ventricular arrhythmias and sudden cardiac death: a systematic review. Heart. 2014 Dec 1;100(23):1831-6.
37. Çetin GY, Yıldırım MN, Zencir C, Karaman K, Çetin M, Sayarlıoğlu M. Evaluation of Tp-e interval and Tp-e/QT ratio in patients with rheumatoid arthritis. Türk Kardiyol Dern Arş - Arch Turk Soc Cardiol 2014;42(1):29-34 doi: 10.5543/tkda.2014.52959
38. Ntusi NA, Piechnik SK, Francis JM, Ferreira VM, Matthews PM, Robson MD, Wordsworth PB, Neubauer S, Karamitsos TD. Diffuse myocardial fibrosis and inflammation in rheumatoid arthritis: insights from CMR T1 mapping. JACC: Cardiovascular Imaging. 2015 May;8(5):526-36.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |